dermatology

News

Almirall takes option on Dermira's eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.

News

AbbVie gets crucial US approval for psoriasis drug Skyrizi

With one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Skyrizi approved in the US.

News

Almirall signs atopic dermatitis R&D deal with Hitgen

Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema.

News

Lilly scores with two Olumiant trials in atopic dermatitis

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which could finally unlock the drug’s potential in the US.

R&D

Biotech strategy and nanomedicine: the pharmaphorum podcast

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Coll

News

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.

Almirall takes option on Dermira's eczema drug lebrikizumab

AbbVie gets crucial US approval for psoriasis drug Skyrizi

Almirall signs atopic dermatitis R&D deal with Hitgen

Lilly scores with two Olumiant trials in atopic dermatitis

Biotech strategy and nanomedicine: the pharmaphorum podcast

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

As Ebola deaths climb, search begins for vaccine

Discover a new era of healthcare panel engagement: Grounded ...

dermatology

Editor's Picks